Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Intellia Thera CS (NQ: NTLA )

14.81 +0.59 (+4.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Thera CS

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Kuehn Law Encourages Investors of Intellia Therapeutics, Inc. to Contact Law Firm
--News Direct-- 
Via News Direct
ARKK’s Tech Bets: Over 500k Roblox Shares Purchased, 1.24M Robinhood Shares Sold
Cathie Wood's ARK Innovation ETF had an active trading week, with notable transactions including the purchase of over 500k Roblox shares and the sale of 1.247 million shares of Robinhood Markets. 
Via Talk Markets
Topics ETFs
Better Cathie Wood Stock: Moderna vs. Intellia
Moderna and Intellia have declined in the double digits over the past year. 
Via The Motley Fool
Hot Stocks: The 3 Best Opportunities for Investing in Biotech
Biotech stocks can offer some of the best risk vs. reward payoff in the stock market. These three are ones to buy now. 
Via InvestorPlace
3 Stocks That Could Be the Next Big Thing in Gene Editing
Gene editing could revolutionize how millions of patients are treated. That could create big opportunities for gene-editing stocks. 
Via InvestorPlace
Is Intellia Therapeutics Stock a Buy Now?
The company's future will depend on its innovative qualities. 
Via The Motley Fool
A Preview Of Intellia Therapeutics's Earnings
Via Benzinga
Is It Too Late to Buy Intellia Therapeutics Stock?
2024 could be an important year for the biotech. 
Via The Motley Fool
Intellia Therapeutics Stock Has 119% Upside, According to 1 Wall Street Analyst
2024 could see the start of its first late-stage clinical trials. 
Via The Motley Fool
A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now
The futures for these two beaten-down stocks could be brighter than their recent pasts. 
Via The Motley Fool
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The popular money manager added to these three existing positions on Monday following disappointing financial updates earlier this month. 
Via The Motley Fool
Cathie Wood's Ark Invest Offloads $6.9M Worth of Coinbase, Robinhood Shares Each Amid Searing Bitcoin Rally — Nvidia Stock Also Shed
On Monday, Cathie Wood-led Ark Invest adjusted its portfolio, notably selling shares of cryptocurrency-related companies such as Robinhood Markets Inc (NASDAQ:HOOD) and Coinbase Global Inc (NASDAQ: 
Via Benzinga
Is CRISPR Therapeutics the NVIDIA of gene editing?
CRISPR Therapeutics AG (NASDAQ: CRSP) made worldwide headlines when it and partner Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) received the first-ever FDA approv 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Earnings Scheduled For February 22, 2024
Companies Reporting Before The Bell • Indivior (NASDAQ:INDV) is likely to report quarterly earnings at $0.28 per share on revenue of $260.00 million. 
Via Benzinga
Cathie Wood Is Betting on This Top Technology: 2 Stocks She Just Bought
These exciting players could deliver explosive growth over time. 
Via The Motley Fool
3 Biotech Stocks to Buy That Have CRISPR-Like Breakthrough Potential
Biotech stocks, namely those involved with gene editing, have been explosive and could see higher highs with strong catalysts. 
Via InvestorPlace
Analysts Say Intellia Therapeutics Stock Could Rise 157% This Year, but Will It Happen?
Good news may be on the way, but it will be a while before it arrives. 
Via The Motley Fool
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis
From ReCode Therapeutics
Via Business Wire
Analysts see over 50% gains in these 2 mid-cap biotech stocks
The outlook for growth has made biotech one of the hottest investments of late - and Wall Street sees big comeback gains ahead in these two biotechs. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
3 Gene Editing Stocks With Unprecedented Surge Potential
While CRISPR will certainly be exciting to watch, here are some other gene-editing stocks with unprecedented surge potential. 
Via InvestorPlace
The 3 Most Undervalued Biotech Stocks to Buy in February 2024
With patience, some of the most undervalued biotech stocks can create massive wealth, such as these three to consider. 
Via InvestorPlace
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The widely followed growth investor keeps making moves. 
Via The Motley Fool
Not Shy Of Buying The Dip, Cathie Wood's Ark Mops Up Over $11M Worth Of Shares In Tesla — Sells Nvidia Stock
Via Benzinga
A Bull Market Is Here: 2 Top Growth Stocks to Buy Hand Over Fist
These biotech innovators have what it takes to soar. 
Via The Motley Fool
Cathie Wood's Ark Invest Snatches Up $4.7M More In Tesla Shares, Invests Equally In This Rocket Company
Via Benzinga
3 Once-in-a-Lifetime Gene Editing Stocks with Unprecedented Surge Potential
Some of the top gene-editing stocks have had immense surge potential. Look at CRISPR Therapeutics, for example. 
Via InvestorPlace
History Says the S&P 500 May Climb in the Triple Digits During This Bull Market. 3 Top Growth Stocks to Buy Before it Does.
Bull markets generally favor growth stocks, so now is a great time to buy quality growth players. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
2 Growth Stocks That Could Rocket 144% and 202% Higher This Year, According to Wall Street
Expectations for these stocks are sky-high, but so are the risks. 
Via The Motley Fool
3 Biotech Stocks to Turn $10,000 Into $1 Million: January 2024
Biotech stocks are some of the most exciting opportunities on the market. Find the right ones with catalysts, and you could make a fortune. 
Via InvestorPlace
Better Growth Stock: Intellia Therapeutics vs. CRISPR Therapeutics
Both companies are going to continue doing high-impact science in 2024. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.